Fibro-inflammatory tumor stroma makes up the physical bulk of pancreatic cancer. Moreover, recent evidence suggests that far from being a passive component in pancreatic ductal epithelial neoplasia, stromal proliferation is crucial for tumor invasiveness and metastasis. The central cell in the pancreatic cancer associated tumor stroma is the activated pancreatic stellate cell (PSC). However, the cellular signals that drive PSC activation from their quiescent state, and hence drive stromal proliferation, are unknown. We postulate that pancreatic dendritic cells (DC) drive PSC activation and are responsible for stromal proliferation and the stepwise progression of pancreatic cancer. This hypothesis is based upon three recent disparate observations from our laboratories: (i) We reported that DC are potent activators of stellate cells in the liver after hepatic injury, (ii) DC expand more than 30-fold in the pancreata of LSL-KrasG12D mice with early PanIN lesions, (iii) DC adoptive transfer to the peri-pancreatic tissues of mice with existing pancreatic inflammation precipitates stromal desmoplasia and pancreatic ductal epithelia dysplasia. Our goal in Aim 1 is to establish a role for DC in pancreatic cancer. Our experimental plan is to initially define the temporal and spatial timeline for DC expansion in the pancreas during the stepwise progression from early pre-invasive lesions to advanced carcinoma in mice and humans. We will then show a cause and effect relationship between DC and pancreatic carcinogenesis using a DC depletion strategy in chimeric LSL-KrasG12D mice.
In Aim 2, using in vitro and in vivo modeling, we will establish DC activation of PSC as cellular mechanism for DC induction of stromal proliferation and tumor progression, and we will explore the cell signaling requirements for DC to effectively engage PSC. We expect our work to have considerable impact on both the understanding of pancreatic tumorgenesis and on novel therapeutics as targeting DC maybe an attractive means to modulate pancreatic cancer progression. Our proposal is highly innovative as it challenges the accepted role of DC as potent anti-tumor agents to one that is pro-tumorogenic by activating PSC and causing expansion of tumor stroma which has direct influence on tumor invasiveness. Our proposal also sheds new light on the 'inflammation-cancer'paradigm as this work will suggests that DC may be a central component in the sequence of inflammation leading to cancer by driving stromal expansion.
Pancreatic cancer is a devastating disease that is fatal in approximately 95% of cases. We postulate that dendritic cells which infiltrate pancreatic tumor are primary stimuli to pancreatic cancer progression by activating the tumor stroma. Our work will show that targeting dendritic cells in pancreatic cancer may be an attractive and novel approach to experimental therapeutics.
|Zambirinis, Constantinos P; Pushalkar, Smruti; Saxena, Deepak et al. (2014) Pancreatic cancer, inflammation, and microbiome. Cancer J 20:195-202|
|Zambirinis, Constantinos P; Ochi, Atsuo; Barilla, Rocky et al. (2013) Induction of TRIF- or MYD88-dependent pathways perturbs cell cycle regulation in pancreatic cancer. Cell Cycle 12:1153-4|
|Rehman, Adeel; Hemmert, Keith C; Ochi, Atsuo et al. (2013) Role of fatty-acid synthesis in dendritic cell generation and function. J Immunol 190:4640-9|
|Mallen-St Clair, Jon; Soydaner-Azeloglu, Rengin; Lee, Kyoung Eun et al. (2012) EZH2 couples pancreatic regeneration to neoplastic progression. Genes Dev 26:439-44|
|Connolly, Michael K; Ayo, Diego; Malhotra, Ashim et al. (2011) Dendritic cell depletion exacerbates acetaminophen hepatotoxicity. Hepatology 54:959-68|
|Bedrosian, Andrea S; Nguyen, Andrew H; Hackman, Michael et al. (2011) Dendritic cells promote pancreatic viability in mice with acute pancreatitis. Gastroenterology 141:1915-26.e1-14|